ALSO NOTED: GSK losing its grip on HIV market; Ranexa gets angina review; Start-up CRO takes flight;and much more...

> Watch out, GlaxoSmithKline. The market for HIV drugs may be expanding, but it's shifting like the San Andreas Fault at the same time, and more than a handful of companies are poised to challenge GSK for dominance. Report

> CV Therapeutics says that federal regulators will review Ranexa as an initial therapy for angina. Release

> A fledgling CRO, Veracity BioTechnology, has flown the incubator to begin research life on its own. President Victor Buckwold, Veracity's sole full-timer at this point, is specializing in testing hepatitis C therapies. Report

> Emergent BioSolutions says that HHS will continue to buy its anthrax vaccine under a fixed $400 million contract. Release

> Schering-Plough has completed the acquisition of Organon. Report

> SGX Pharmaceuticals will get $25 million through a private placement. Release

> Despite a black box warning, atypical antipsychotics do big business in nursing homes. Report

> VaxInnate is in a tight race to develop the first "universal" flu vaccine that would be able to tackle a variety of influenzas and do away with the annual winter jab. Report

> A new compound has proved effective in animal studies in restoring electrical activity in the muscles of muscular dystrophy patients. Report

> A small gene therapy study involving a handful of Parkinson's patients has produced impressive data indicating that they may be on to a potential breakthrough. Report

And Finally... PS3 gamers and a team of internationally renowned scientists have joined forces on global molecular project. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.